A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia

• DOI: 10.1016/j.ajog.2021.05.018
• Publication Date: 2021-05-24T07:59:41Z
• Authors: Maged M. Costantine; Holly West; Katherine L. Wisner; Steve Caritis; Shannon Clark; Raman Venkataramanan; Catherine S. Stika; Erik Rytting; Xiaoming Wang; Mahmoud S. Ahmed; Elizabeth Welch; Wayne Snodgrass; Tatiana Nanovskaya; Svetlana Patrikeeva; George Saade; Gary Hankins; Emily Pinheiro; Kelly O’Shea; Minaz Cattan; Gabrielle Mesches; Jody Ciolino; Alfred L. George; Dawn Fischer; Donna DeAngeles; Zhaoxia Ren
• Keywords: Adult; Pilot Projects; Prenatal Care; 3. Good health; Young Adult; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Double-Blind Method; Pre-Eclampsia; Pregnancy; Pregnancy Trimester, Second; Humans; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin

(Am J Obstet Gynecol. 2021;225:666.e1–15) Preeclampsia affects up to 8% of pregnancies and is associated with maternal and neonatal morbidities. Preeclampsia also shares characteristics with other cardiovascular diseases. Pravastatin has been considered a possible method of preventing preeclampsia, supported by preclinical studies and pilot clinical studies using 10 mg pravastatin in high-risk patients. This study aimed to determine the safety and pharmacokinetic parameters of 20 mg pravastatin in patients with a high risk of preeclampsia.